Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NUV-422 + Fulvestrant in HR+HER2- Advanced Breast Cancer
NCT05191004Phase 2Withdrawn
- Sponsor
- Nuvation Bio
- Start
- Sep 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inixaciclib in Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+), sponsored by Nuvation Bio. Planned start Sep 2022; status: withdrawn.
02
Drugs
inixaciclib
03
Conditions
Hormone Receptor-Negative HER2-Positive Breast Cancer (HR-/HER2+)
Beyond the preview
Go deeper on NCT05191004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191004.